Your browser doesn't support javascript.
loading
Kynurenine 3-monooxygenase deficiency induces depression-like behavior via enhanced antagonism of α7 nicotinic acetylcholine receptors by kynurenic acid.
Mori, Yuko; Mouri, Akihiro; Kunisawa, Kazuo; Hirakawa, Mami; Kubota, Hisayoshi; Kosuge, Aika; Niijima, Moe; Hasegawa, Masaya; Kurahashi, Hitomi; Murakami, Reiko; Hoshi, Masato; Nakano, Takashi; Fujigaki, Suwako; Fujigaki, Hidetsugu; Yamamoto, Yasuko; Nabeshima, Toshitaka; Saito, Kuniaki.
Afiliación
  • Mori Y; Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Science, Aichi, Japan.
  • Mouri A; Department of Regulatory Science for Evaluation & Development of Pharmaceuticals & Devices, Fujita Health University Graduate School of Health Science, Aichi, Japan; Japanese Drug Organization of Appropriate Use and Research, Aichi, Japan. Electronic address: mouri@fujita-hu.ac.jp.
  • Kunisawa K; Department of Regulatory Science for Evaluation & Development of Pharmaceuticals & Devices, Fujita Health University Graduate School of Health Science, Aichi, Japan; Advanced Diagnostic System Research Laboratory, Fujita Health University Graduate School of Health Science, Aichi, Japan.
  • Hirakawa M; Department of Regulatory Science for Evaluation & Development of Pharmaceuticals & Devices, Fujita Health University Graduate School of Health Science, Aichi, Japan.
  • Kubota H; Department of Regulatory Science for Evaluation & Development of Pharmaceuticals & Devices, Fujita Health University Graduate School of Health Science, Aichi, Japan.
  • Kosuge A; Department of Regulatory Science for Evaluation & Development of Pharmaceuticals & Devices, Fujita Health University Graduate School of Health Science, Aichi, Japan.
  • Niijima M; Department of Regulatory Science for Evaluation & Development of Pharmaceuticals & Devices, Fujita Health University Graduate School of Health Science, Aichi, Japan.
  • Hasegawa M; Department of Regulatory Science for Evaluation & Development of Pharmaceuticals & Devices, Fujita Health University Graduate School of Health Science, Aichi, Japan.
  • Kurahashi H; Department of Regulatory Science for Evaluation & Development of Pharmaceuticals & Devices, Fujita Health University Graduate School of Health Science, Aichi, Japan.
  • Murakami R; Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Science, Aichi, Japan.
  • Hoshi M; Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Science, Aichi, Japan.
  • Nakano T; Department of Computational Biology, School of Medicine, Fujita Health University, Aichi, Japan.
  • Fujigaki S; Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Science, Aichi, Japan.
  • Fujigaki H; Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Science, Aichi, Japan.
  • Yamamoto Y; Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Science, Aichi, Japan.
  • Nabeshima T; Advanced Diagnostic System Research Laboratory, Fujita Health University Graduate School of Health Science, Aichi, Japan; Japanese Drug Organization of Appropriate Use and Research, Aichi, Japan.
  • Saito K; Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Science, Aichi, Japan; Japanese Drug Organization of Appropriate Use and Research, Aichi, Japan.
Behav Brain Res ; 405: 113191, 2021 05 07.
Article en En | MEDLINE | ID: mdl-33607168
ABSTRACT
Tryptophan (TRP) is metabolized via the kynurenine (KYN) pathway, which is related to the pathogenesis of major depressive disorder (MDD). Kynurenine 3-monooxygenase (KMO) is a pivotal enzyme in the metabolism of KYN to 3-hydroxykynurenine. In rodents, KMO deficiency induces a depression-like behavior and increases the levels of kynurenic acid (KA), a KYN metabolite formed by kynurenine aminotransferases (KATs). KA antagonizes α7 nicotinic acetylcholine receptor (α7nAChR). Here, we investigated the involvement of KA in depression-like behavior in KMO knockout (KO) mice. KYN, KA, and anthranilic acid but not TRP or 3-hydroxyanthranilic acid were elevated in the prefrontal cortex of KMO KO mice. The mRNA levels of KAT1 and α7nAChR but not KAT2-4, α4nAChR, or ß2nAChR were elevated in the prefrontal cortex of KMO KO mice. Nicotine blocked increase in locomotor activity, decrease in social interaction time, and prolonged immobility in a forced swimming test, but it did not decrease sucrose preference in the KMO KO mice. Methyllycaconitine (an α7nAChR antagonist) antagonized the effect of nicotine on decreased social interaction time and prolonged immobility in the forced swimming test, but not increased locomotor activity. Galantamine (an α7nAChR allosteric agonist) blocked the increased locomotor activity and prolonged immobility in the forced swimming test, but not the decreased social interaction time in the KMO KO mice. In conclusion, elevation of KA levels contributes to depression-like behaviors in KMO KO mice by α7nAChR antagonism. The ameliorating effects of nicotine and galantamine on depression-like behaviors in KMO KO mice are associated with the activation of α7nAChR.
Asunto(s)
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Conducta Animal / Corteza Prefrontal / Antagonistas Nicotínicos / Agonistas Nicotínicos / Depresión / Quinurenina 3-Monooxigenasa / Receptor Nicotínico de Acetilcolina alfa 7 / Ácido Quinurénico Idioma: En Revista: Behav Brain Res Año: 2021 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Conducta Animal / Corteza Prefrontal / Antagonistas Nicotínicos / Agonistas Nicotínicos / Depresión / Quinurenina 3-Monooxigenasa / Receptor Nicotínico de Acetilcolina alfa 7 / Ácido Quinurénico Idioma: En Revista: Behav Brain Res Año: 2021 Tipo del documento: Article